Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | RGS12 | O14924 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | GNAI1 | P63096 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | HPGD | P15428 | 2/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.98 |
| ▸ | GMNN | O75496 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL140170 | 1.00 | DRD2 (1.00) | DRD2ALDH1A1MAPTMAPK1RGS12 | |
| SCHEMBL29602749 | 1.00 | DRD2 (1.00) | DRD2ALDH1A1MAPTMAPK1RGS12 | |
| SCHEMBL8344207 | 1.00 | DRD2 (1.00) | DRD2ALDH1A1MAPTMAPK1RGS12 | |
| Bromide SCHEMBL31027963 | 0.99 | MAPT (1.00) | DRD2ALDH1A1MAPTMAPK1RGS12 | |
| Bromide SCHEMBL4923286 | 0.99 | MAPT (1.00) | DRD2ALDH1A1MAPTMAPK1RGS12 | |
| Bromide SCHEMBL4923294 | 0.99 | MAPT (1.00) | DRD2ALDH1A1MAPTMAPK1RGS12 | |
| SCHEMBL12877906 | 0.89 | DRD2 (0.80) | DRD2ALDH1A1MAPTMAPK1RGS12 | |
| SCHEMBL518062 | 0.86 | ALDH1A1 (1.00) | DRD2ALDH1A1MAPTMAPK1RGS12 | |
| SCHEMBL8097389 | 0.86 | DRD1 (0.77) | DRD2ALDH1A1MAPTMAPK1RGS12 | |
| SCHEMBL1325960 | 0.86 | MAPT (1.00) | DRD2ALDH1A1MAPTMAPK1RGS12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130039933-A1 | STING (STIMULATOR OF INTERFERON GENES), A REGULATOR OF INNATE IMMUNE RESPONSES | UNIVERSITY OF MIAMI (US) | 2013-02-14 | — | — | US | claimed |
| EP-3745862-B1 | D1 DOPAMINE RECEPTOR AGONISTS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4378532-A2 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | Mayo Foundation for Medical Education and Research (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-4003348-B1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2024-04-03 | — | — | EP | disclosed |
| US-20230346740-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-11-02 | — | — | US | disclosed |
| US-20210403432-A1 | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING METABOLIC DISEASES AND/OR A CLINICAL CONDITION THEREOF | CK BIOTECH INC (KR) | 2021-12-30 | — | — | US | disclosed |
| US-20210323918-A1 | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING A GROWTH RELATED DISEASE AND/OR A CLINICAL CONDITION THEREOF | CK BIOTECH INC (KR) | 2021-10-21 | — | — | US | disclosed |
| US-20210038561-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-02-11 | — | — | US | disclosed |
| WO-2020079569-A1 | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING METABOLIC DISEASES AND/OR A CLINICAL CONDITION THEREOF | Ck Biotechnology Co. (KR) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020079570-A1 | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING A GROWTH RELATED DISEASE AND/OR A CLINICAL CONDITION THEREOF | Ck Biotechnology Co. (KR) | 2020-04-23 | — | — | WO | disclosed |
| US-7514583-B2 | bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis | PROTEOTECH, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090076019-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE | MOUNT SINAI HOSPITAL (CA) | 2009-03-19 | — | — | US | disclosed |
| US-20090069432-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTEOTECH INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069432-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTEOTECH INC. | 2009-03-12 | — | — | US | disclosed |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTAMED, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTAMED, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038561-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD2 4879/4885ALDH1A1 1390/4885MAPT 3670/4885 |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | NR1H2, NR1H3, NR1H4 | DRD2 1998/4885ALDH1A1 1308/4885MAPT 3290/4885 |
| US-20210323918-A1 | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING A GROWTH RELATED DISEASE AND/OR A CLINICAL CONDITION THEREOF | CXXC5, DIAPH1, CBX2 | DRD2 4808/4885ALDH1A1 4270/4885MAPT 4292/4885 |
| US-20210403432-A1 | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING METABOLIC DISEASES AND/OR A CLINICAL CONDITION THEREOF | CBX6, CXXC5, PNLIP | DRD2 4797/4885ALDH1A1 3441/4885MAPT 3136/4885 |
| US-20230346740-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD2 4879/4885ALDH1A1 1390/4885MAPT 3670/4885 |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | IAPP, SNCA, APP | DRD2 2602/4885ALDH1A1 1886/4885MAPT 17/4885 |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | SNCA, PARK7, COMT | DRD2 513/4885ALDH1A1 2540/4885MAPT 6/4885 |
| US-20090069432-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | IAPP, APP, SNCA | DRD2 351/4885ALDH1A1 2505/4885MAPT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.